Latest news with #QMS
Time of India
13-05-2025
- Automotive
- Time of India
Revolt Motors secures ISO Certification for quality management
Indian electric motorcycle manufacturer, Revolt Motors , has received ISO 9001:2015 certification for its Quality Management System (QMS). The certification, issued by an international testing and certification body, confirms that the company meets global standards in product design, production, supply chain, and customer service. ISO 9001:2015 is an internationally recognised standard for quality management systems and is granted to organisations that demonstrate compliance with specific quality benchmarks. Structured approach and strategic plans Anjali Rattan Nashier, Chairperson, RattanIndia Enterprises, said, 'This certification is a proud moment for all of us at R ev olt. It is a reflection of our tireless pursuit of quality, innovation, and operational excellence. As we expand to new geographies and strengthen our position in the EV segment, this global certification reinforces the trust our customers and partners place in us.' Revolt's certification highlights its structured processes in product development, manufacturing controls, and customer-focused delivery. The company states that the certification aligns with its long-term strategy, which includes international expansion and enhancing after-sales service. The company noted that the certification supports its credibility among business partners, collaborators, and institutional stakeholders. It applies across its product range, from the RV400 to the BlazeX.
Business Standard
13-05-2025
- Automotive
- Business Standard
Revolt Motors achieves ISO 9001:2015 certification
Revolt Motors has been awarded the prestigious ISO 9001:2015 certification for its robust Quality Management System (QMS). The certification issued by one of the world's leading testing and certification bodies, validates Revolt's commitment to consistent quality, process excellence, and customer satisfaction across its operations. ISO 9001:2015 is the world's most recognized standard for quality management, awarded only to organizations that meet stringent international benchmarks across product design, production, supply chain, and customer service. With this recognition, Revolt joins an elite group of electric vehicle manufacturers adhering to globally standardized quality practices. Powered by Capital Market - Live News
Press and Journal
08-05-2025
- Business
- Press and Journal
Trade group says extra north and north-east coos can boost Scottish economy
A couple more cows per farm in Aberdeenshire and Moray each year, plus an extra pair of cattle on every croft in the Highlands and Islands will deliver a huge boost to the Scottish economy, a new report claims. It could be worth as much as £76 million annually to the nation in gross value added (GVA) terms, Quality Meat Scotland (QMS) says. The same investment on farms across Angus, Perth & Kinross, Stirlingshire and other parts of Scotland can also contribute to this level of growth, the trade body suggests. Its latest economic modelling for the red meat sector estimates six to eight more cows per herd in total over three to four years could generate an additional £281m in output. The figures are based on the current reproduction rate for cattle north of the border. And the report goes on to forecast what may happen if UK beef production does not grow. Net imports will likely increase by around 124,000 tons by 2030, QMS warns. The red meat marketing group also highlights that beef processing capacity in Scotland is currently underused, operating at just 69–73%. Launching the report, published today, QMS chairwoman Kate Rowell said: 'Our evidence centre points to a clear growth opportunity by servicing domestic demand which, if we don't seize, others certainly will through imports. 'We want the Scottish herd to grow by close to 80,000 cattle.' This equates to an 'attainable' couple more cows per herd each year, Ms Rowell said. She added: 'Nationally, this goal would see the herd return to the levels seen in the mid-2010s. With the strength in our beef prices at the moment, now is the ideal time to invest. If our production continues to decline, it will intensify adverse knock-on effects across the supply chain.' Kate Rowell, QMS 'Scotland has the infrastructure to support this growth, with the processing sector currently operating at only 69-73% capacity. 'If our production continues to decline, it will intensify adverse knock-on effects across the supply chain from feed, haulage and auctioneers to processors, butchers, retailers and, finally, consumers.' Key research findings in the QMS report include: QMS also warns a rise in global demand for UK beef could further exacerbate supply issues domestically, requiring even greater import volumes to balance the market. Its report adds: 'Given that UK beef production is typically more efficient and lower in emissions than international alternatives, increasing imports contradicts global sustainability goals, including commitments under the Paris Agreement.' According to Ms Rowell, there is 'no one silver bullet solution' to reversing the decline in the national beef herd and increasing productivity in the sector. But it would be 'utterly perverse' from a security, quality and environmental perspective to risk losing a critical part of the national food system and accept an increase in overseas red meat imports, she said. In the coming months QMS will be 'working with partners to raise awareness, engage with and support producers and traders, politicians and decision-makers, and consumers to boost confidence in our at-home market opportunity and encourage action'.
Yahoo
24-03-2025
- Business
- Yahoo
KRTL Holding Group Announces KRTL Biotech Inc. Signs MOU with Industria Químico Farmacéutica Sigma Corp. S.R.L. to Pursue Strategic International Merger
Lakewood, CO, March 24, 2025 (GLOBE NEWSWIRE) -- KRTL Holding Group Inc. (OTC: KRTL), a diversified holding company operating through its subsidiaries KRTL Biotech, Inc. and KRTL International Corp., is pleased to announce that its wholly owned subsidiary, KRTL Biotech Inc., has signed a Memorandum of Understanding (MOU) with Industria Químico Farmacéutica Sigma Corp. S.R.L. ("Sigma") of Bolivia. This MOU establishes the framework for a strategic international merger between the two pharmaceutical entities. Under the terms of the MOU, KRTL Biotech and Sigma have agreed on key merger provisions, including a shared governance structure, consolidated financial oversight, and aligned Quality Management Systems (QMS). Sigma will maintain full operational autonomy in Bolivia, while the partnership focuses on cross-border compliance, coordinated financial operations, and integrated strategic governance. 'This MOU marks a pivotal milestone for KRTL Biotech and a transformative step in our international expansion,' stated Cesar Herrera, CEO of KRTL Holding Group Inc. 'By joining forces with Sigma, we are strengthening our global regulatory capabilities and expanding pharmaceutical production capacity across U.S. and South American markets.' As part of the agreement, Sigma will receive equity in KRTL Holding Group Inc., including one (1) Special 2021 Series A Preferred Share and representation on KRTL Holding's Board of Directors. In addition, key Sigma executives will receive individual common stock allocations to align long-term incentives. Financial integration will be managed through SIGMARTL Corp, a U.S.-based financial management entity designed to track global revenue, ensure compliance, and oversee profit-sharing mechanisms. The legal structuring and regulatory due diligence of the merger is being managed by a specialized law firm in South America, with experience in international mergers and pharmaceutical regulations. The final Business Merger Agreement, currently under development, will formalize the merger upon securing all necessary legal and financial conditions. The MOU outlines a strategic plan to consolidate Sigma's manufacturing operations and revenue streams into KRTL Biotech. This integration is intended to facilitate the import and commercialization of Sigma's pharmaceutical products in the United States under KRTL's regulatory and distribution framework. The parties believe that the merger will significantly enhance operational efficiency, enabling Sigma's production facilities—currently running at approximately 40% capacity—to scale output and achieve full utilization. Based on current figures, Sigma generates annual revenues exceeding $20 million, and the combined entity anticipates the potential to double that figure within the first two years following full integration. This initiative builds upon KRTL Biotech's ongoing strategy to establish itself as a central player in international pharmaceutical production, API oversight, and regulatory compliance. The combined operations will enhance production capacity, open new markets, and foster innovation in therapeutic development. About KRTL Holding Group Inc. KRTL Holding Group Inc. is a dynamic holding company operating through its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. These subsidiaries specialize in biopharmaceutical innovation, international trade, and compliance-driven healthcare advancements. By leveraging strategic mergers, acquisitions, and joint ventures, KRTL Holding Group continues to push the boundaries of scientific research, regulatory compliance, and global business solutions. For more information, please visit: Forward-Looking Statements This press release contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, anticipated business developments, regulatory advancements, and strategic growth plans. Such forward-looking statements involve known and unknown risks that may cause actual results to differ materially from those expressed or implied. KRTL Holding Group assumes no obligation to update or revise forward-looking statements, except as required by law. Any updates will be made in accordance with applicable SEC regulations and disclosure obligations. Readers are cautioned not to place undue reliance on forward-looking statements. CONTACT: info@ info@ info@ in to access your portfolio
Associated Press
20-02-2025
- Business
- Associated Press
An Introduction to ISO 13485: 2016 - Quality Management System (QMS) for Medical Devices Training Course (ONLINE EVENT: March 13, 2025)
The 'An Introduction to ISO 13485: 2016 - Quality Management System (QMS) for Medical Devices Training Course' conference has been added to offering. This course has been specifically designed to provide an essential introduction to ISO 13485 and the QMS and provides a comprehensive and valuable overview of the requirements and responsibilities involved. The ISO 13485:2016 standard specifies requirements for a Quality Management System (QMS) where an organisation needs to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements. Such medical device organisations can be involved in one or more stages of the life-cycle, including; design and development, production, storage and distribution, installation, or servicing of a medical device, and design and development or provision of associated activities such as technical support. ISO 13485:2016 can also be used by suppliers or external parties that provide products, including QMS-related services to such organisations. Where ever you and your company sit within the medical device arena this is an excellent opportunity to become appraised of the requirements. This course will be useful as a refresher or for those new to the medical device industry. Benefits of Attending Certifications CPD: 6 hours for your records Certificate of completion Who Should Attend: Quality managers Quality assurance personnel Regulatory affairs managers Internal and external auditors Medical device designers and developers All those who are involved with the implementation of the QMS Agenda: Welcome and Introduction Objectives for the day What do you want from the day? Overview of ISO 13485:2016 Introduction to standards and their use Use of ISO13485:2016 Conformity assessment Cost/Benefit of Quality Defining the Scope and Objectives of Your QMS Quality policy Quality objectives Quality manual Documentation Requirements Requirements Document control Resource management Training Workshop Exercise: Writing Quality Policy and Objectives Intellectual Property (IP) to CE Marking in a QMS Design and development Supplier Management Economic Operators Supplier management Supply chain control Direct Processes Change management Risk Management Control of non-conforming product Post Market Surveillance What is it? The elements Reactive vs Proactive Workshop Exercise: Quality Management - Functional Interaction Summary and Key Take Aways Speakers: Stuart Angell Director IVDeology Ltd Stuart Angell, This MDTI expert is a joint director in his own consultancy specialising in global regulatory affairs strategy and compliance for in vitro diagnostics and medical devices focusing on the transition to the new IVD/Medical Device Regulations, MDSAP and ISO13485:2016. He has over 15 years in the IVD industry and in previous roles has been responsible for designing, reviewing and maintaining regulatory frameworks for self-declared and annex list II products including technical documentation for EU and global submissions (FDA, Health Canada, TGA, Russia, Latin America). He has an excellent understanding of risk management, Post Market Surveillance (PMS) and vigilance. For more information about this conference visit is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Laura Wood, Senior Press Manager [email protected] E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: MEDICAL DEVICES HEALTH Copyright Business Wire 2025. PUB: 02/20/2025 07:10 AM/DISC: 02/20/2025 07:10 AM
